Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Izutsu, Koji [1 ]
Goto, Hideki [2 ]
Kizaki, Masahiro [3 ]
Yamaguchi, Masaki [4 ]
Fukuhara, Noriko [5 ]
Kato, Koji [6 ]
Saito, Toko [7 ]
Terui, Yasuhito [8 ]
Okubo, Sumiko [9 ]
Soshin, Tomomi [9 ]
Mukherjee, Nabanita [10 ]
Honda, Hideyuki [9 ]
Badawi, Mohamed [10 ]
Ross, Jeremy [10 ]
Ishizawa, Kenichi [11 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hokkaido Univ Hosp, Hokkaido, Japan
[3] Saitama Med Ctr, Saitama, Japan
[4] Ishikawa Prefecture Cent Hosp, Kanazawa, Ishikawa, Japan
[5] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[6] Kyushu Univ Hosp, Fukuoka, Japan
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Saitama Med Univ Hosp, Saitama, Japan
[9] Abbvie GK, Tokyo, Japan
[10] AbbVie Inc, N Chicago, IL USA
[11] Yamagata Univ Hosp, Yamagata, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.280
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO50-5
引用
收藏
页码：S1428 / S1428
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Goto, Hideki
    Ito, Satoshi
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Zeng, Jiewei
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy A.
    Izutsu, Koji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
  • [2] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Hideki Goto
    Satoshi Ito
    Masahiro Kizaki
    Masaki Yamaguchi
    Noriko Fukuhara
    Koji Kato
    Toko Saito
    Yasuhito Terui
    Sumiko Okubo
    Tomomi Soshin
    Jiewei Zeng
    Hideyuki Honda
    Mohamed Badawi
    Jeremy A. Ross
    Koji Izutsu
    International Journal of Clinical Oncology, 2024, 29 : 232 - 240
  • [3] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [4] Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Nishikawa, Tomoaki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (02) : 98 - 100
  • [5] Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
    Michael Wang
    Radhakrishnan Ramchandren
    Robert Chen
    Lionel Karlin
    Geoffrey Chong
    Wojciech Jurczak
    Ka Lung Wu
    Mark Bishton
    Graham P. Collins
    Paul Eliadis
    Frédéric Peyrade
    Yihua Lee
    Karl Eckert
    Jutta K. Neuenburg
    Constantine S. Tam
    Journal of Hematology & Oncology, 14
  • [6] Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
    Wang, Michael
    Ramchandren, Radhakrishnan
    Chen, Robert
    Karlin, Lionel
    Chong, Geoffrey
    Jurczak, Wojciech
    Wu, Ka Lung
    Bishton, Mark
    Collins, Graham P.
    Eliadis, Paul
    Peyrade, Frederic
    Lee, Yihua
    Eckert, Karl
    Neuenburg, Jutta K.
    Tam, Constantine S.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [7] Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
    Portell, Craig A.
    Wages, Nolan A.
    Kahl, Brad S.
    Budde, Lihua E.
    Chen, Robert W.
    Cohen, Jonathon B.
    Varhegyi, Nikole E.
    Petroni, Gina R.
    Williams, Michael E.
    BLOOD ADVANCES, 2022, 6 (05) : 1490 - 1498
  • [8] OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.
    Le Gouill, Steven
    Davies, Andrew
    Bouabdallah, Kamal
    Chiron, David
    Rule, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Shibayama, Hirohiko
    Choi, Ilseung
    Hatake, Kiyohiko
    Uchida, Toshiki
    Nishikori, Momoko
    Kinoshita, Tomohiro
    Matsuno, Yoshihiro
    Nishikawa, Tomoaki
    Takahara, Satoko
    Tobinai, Kensei
    CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
  • [10] Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study
    Tam, Constantine S.
    Ramchandren, Radhakrishnan
    Chen, Robert
    Karlin, Lionel
    Chong, Geoffrey
    Jurczak, Wojciech
    Wu, Ka Lung
    Bishton, Mark
    Collins, Graham P.
    Eliadis, Paul
    Peyrade, Frederic
    Szafer-Glusman, Edith
    Lee, Yihua
    Eckert, Karl
    Neuenburg, Jutta K.
    Wang, Michael
    BLOOD, 2020, 136
12345